Previous preclinical studies of miransertib using tumour xenografts showed that the minimum dose that has an impact on tumour volume is 75 mg/kg (Yu et al, 2017); thus, we first evaluated this dose to assess miransertib for preventing the formation of Pik3ca‐driven vascular malformations. Here, PIK3CA is linked to vascular malformation.